French pharmaceutical company Sanofi has reported results from its Phase III IRAKLIA trial, which evaluated Sarclisa (isatuximab) as a potential treatment for multiple myeloma (MM). The trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback